Targeting WNT1-inducible Signaling Pathway Protein 2 Alters Human Breast Cancer Cell Susceptibility to Specific Lysis Through Regulation of KLF-4 and MiR-7 Expression
Overview
Authors
Affiliations
The molecular basis for the resistance of tumor cells to cell-mediated cytotoxicity remains poorly understood and thus poses a major challenge for cancer immunotherapy. The present study was designed to determine whether the WNT1-inducible signaling pathway protein 2 (WISP2, also referred to as CCN5), a key regulator of tumor cell plasticity, interferes with tumor susceptibility to cytotoxic T-lymphocyte (CTL)-mediated lysis. We found that silencing WISP2 signaling in human breast adenocarcinoma MCF7 cells impairs CTL-mediated cell killing by a mechanism involving stem cell marker Kruppel-like factor-4 (KLF-4) induction and microRNA-7 (miR-7) downregulation. Inhibition of transforming growth factor beta (TGF-β) signaling using the A83-01 inhibitor in MCF7-shWISP2 cells resulted in a significant reversal of the epithelial-to-mesenchymal-transitioned (EMT) phenotype, the expression of KLF-4 and a partial recovery of target susceptibility to CTLs. More importantly, we showed that silencing KLF-4 was accompanied by a reduction in MCF7-shWISP2 resistance to CTLs. Using human breast cancer tissues, we demonstrated the coexpression of KLF-4 with EMT markers and TGF-β pathway signaling components. More importantly, we found that KLF-4 expression was accompanied by miR-7 inhibition, which is partly responsible for impairing CTL-mediated lysis. Thus, our data indicate that WISP2 has a role in regulating tumor cell susceptibility through EMT by inducing the TGF-β signaling pathway, KLF-4 expression and miR-7 inhibition. These studies indicate for the first time that WISP2 acts as an activator of CTL-induced killing and suggests that the loss of its function promotes evasion of immunosurveillance and the ensuing progression of the tumor.
KLF4: a multifunctional nexus connecting tumor progression and immune regulation.
Ju Y, Xiao W, Mathis B, Shi Y Front Immunol. 2025; 16:1514780.
PMID: 39995670 PMC: 11848521. DOI: 10.3389/fimmu.2025.1514780.
Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y Cancer Sci. 2023; 114(12):4511-4520.
PMID: 37991442 PMC: 10728009. DOI: 10.1111/cas.15986.
EMT-induced immune evasion: connecting the dots from mechanisms to therapy.
Imodoye S, Adedokun K Clin Exp Med. 2023; 23(8):4265-4287.
PMID: 37966552 DOI: 10.1007/s10238-023-01229-4.
Zhou L, Wu J, Ruan M, Xiao Y, Lan H, Wu Q Breast Cancer Res. 2023; 25(1):115.
PMID: 37794509 PMC: 10548745. DOI: 10.1186/s13058-023-01721-5.
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy.
Abou Khouzam R, Lehn J, Mayr H, Clavien P, Wallace M, Ducreux M Cancers (Basel). 2023; 15(4).
PMID: 36831579 PMC: 9953896. DOI: 10.3390/cancers15041235.